Regulatory and market intelligence · cannabis & hemp

From seed to market, what the rules require at every stage.

Under Brazil’s 2026 regulatory framework, companies can now grow hemp for medical use and make, sell and export cannabis products. Since 2022, Green Growth has combined regulatory knowledge with market intelligence to connect every stage of this chain, from cultivation to the investment that helps the sector grow.

Section 01 · Value chain

One plant moves through five stages. At each one, the rules change.

Around the world, hemp supplies medicines, food, textiles, construction and energy. In Brazil, for now, only the medical and pharmaceutical route has rules. Scroll and follow the plant: what the law requires at each stage, where operations tend to fail and where the business is.

Genetics & cultivation

RDC 1.013/2026 created regulated domestic cultivation, for medical, pharmaceutical, research and export purposes. This is where agribusiness enters the chain, and legal structure decides who may plant.

Rule
Hemp cultivation with up to 0.3% THC by legal entities only, with an ANVISA Special Authorization, a prior health inspection and seed-to-batch traceability. Seed imports follow MAPA Ordinance 1.342/2025.
Risk
The authorization belongs to the company, not the farmer. Without the right legal entity and an origin record from the seed, the project stops before planting.
Opportunity
Those who get structured first are likely to become suppliers of traceable biomass to the pharmaceutical industry, in Brazil or abroad: RDC 1.023/2026 allows cultivation for export, backed by a buyer’s contract or letter of intent. Growing for fiber, grain or construction still depends on rules from the Agriculture Ministry (MAPA).

Uses of this stage worldwide

  • Seed stock
  • Biomass
  • Phytoremediation
  • Carbon credits
Talk about this stage

Extraction & processing

The plant is split into fractions, and each becomes an input: extract, oil, fiber, biomass. This is the stage most exposed to health inspections.

Rule
Good manufacturing practices, control of substances and batch-by-batch traceability, required by the new framework.
Risk
When a batch fails, someone is liable. Without separate risks in the corporate structure, the whole operation is liable.
Opportunity
Bring cultivation and extraction into the same structure, with risks kept separate, and treat the seed-to-batch record as an asset the buyer can audit.

Uses of this stage worldwide

  • CBD extracts
  • Terpenes
  • Oil
  • Plant protein
  • Textile fiber
  • Pulp and paper
  • Biomass
  • Biochar
Talk about this stage

Manufacturing & product approval

Each fraction becomes a finished product. On the medical route, this is where the product gets the authorization to be sold. Tax treatment is also decided here.

Rule
RDC 1.015/2026, replacing RDC 327/2019: oral, inhaled, buccal, sublingual and dermatological routes, plus new quality and labeling criteria. Cosmetics, food and smokable products remain excluded.
Risk
The Health Authorization is cancelled if the product does not reach the market within one year. Launching a portfolio without a defined tax position leaves the margin exposed to the transition.
Opportunity
The new routes open up the portfolio. RDC 1.015/2026 provides for compounding with isolated CBD only (art. 72), but the activity depends on rules still to be issued by ANVISA.

Uses of this stage worldwide

  • Phytopharmaceuticals
  • Dermocosmetics
  • Plant protein
  • Hempcrete
  • Bioplastics
  • Animal feed
Talk about this stage

Distribution & access

Imports, controlled logistics and dispensing. In Brazil, the medical product reaches the patient through the pharmacy, with a prescription.

Rule
RDC 1.015/2026 also sets the rules for prescribing, dispensing and control in pharmacies and drugstores.
Risk
The tax burden weighs on imports today, and the move to CBS and IBS means repricing contracts across the chain throughout the transition.
Opportunity
Distributors and pharmacy chains that prepare now will reach the domestic product sooner, once authorized cultivation scales up.

Uses of this stage worldwide

  • Phytopharmaceuticals
  • Dermocosmetics
  • Oil
  • Textile fiber
  • Pulp and paper
  • Hempcrete
Talk about this stage

Market & capital

The stage that gives value to the others: mergers and acquisitions, fundraising, joint ventures and partnerships between agribusiness, extraction and industry.

Rule
RDC 1.023/2026: exports of cannabis APIs and products made in Brazil, and hemp cultivation for export, backed by a buyer’s contract or letter of intent. The RDC 1.014/2026 sandbox is for patient associations, not for companies.
Risk
In due diligence, what counts is what is on paper. Compliance without documents becomes a discount on the price.
Opportunity
Fundraising backed by compliance the investor can verify and by export contracts that prove demand. Whole-plant revenue, such as carbon, bioenergy and biomaterials, depends on rules Brazil does not have yet.

Uses of this stage worldwide

  • All uses of the plant
Talk about this stage
Reference map

Where each part of the plant enters the chain

OpenClose

Worldwide uses of each fraction, stage by stage, and the status of each one in Brazil today. Use it as a map to place your operation.

  • Regulated path in Brazil
  • No specific rules in Brazil yet
  • Excluded by the current framework (cosmetics, food, smokables)
Genetics & cultivationExtractionManufacturingDistributionMarket & capital
Flower—CBD extractsregulated pathTerpenesno rules yetPhytopharmaceuticalsregulated pathDermocosmeticsexcludedPhytopharmaceuticalsregulated pathDermocosmeticsexcludedCBD extractsregulated pathPhytopharmaceuticalsregulated pathDermocosmeticsexcludedTerpenesno rules yet
Stalk—Textile fiberno rules yetPulp and paperno rules yetHempcreteno rules yetBioplasticsno rules yetTextile fiberno rules yetPulp and paperno rules yetHempcreteno rules yetTextile fiberno rules yetPulp and paperno rules yetHempcreteno rules yetBioplasticsno rules yet
LeavesBiomassregulated pathBiomassregulated pathAnimal feedno rules yet—Biomassregulated pathBioenergyno rules yetAnimal feedno rules yet
Grain & seedSeed stockregulated pathOilexcludedPlant proteinexcludedPlant proteinexcludedOilexcludedSeed stockregulated pathOilexcludedPlant proteinexcluded
RootPhytoremediationno rules yetCarbon creditsno rules yetBiocharno rules yet——Phytoremediationno rules yetCarbon creditsno rules yetBiocharno rules yet

Sources: STJ, IAC 16 (2024); ANVISA, RDCs 1.013, 1.015 and 1.023/2026; MAPA, Ordinance 1.342/2025. For information only, subject to ongoing regulation.

Section 02 · Market & tax

The sector is setting records while its tax bill is being rewritten

More patients, more revenue and a new health framework. At the same time, the tax reform replaces PIS, Cofins, ICMS and ISS with CBS and IBS over a multi-year transition. Anyone setting prices, contracts and structure now is deciding under both systems.

1.11M

medical cannabis patients in Brazil in 2026, 27% more than in 2025. This is the sum of the three access routes; someone using more than one may be counted twice.

Kaya Mind · 2026 Yearbook
R$1.14bn

in estimated sector revenue in 2026, 17% above 2025. It is the first year above R$ 1 billion.

Kaya Mind · 2026 Yearbook
CBS + IBS

replace PIS, Cofins, ICMS and ISS over the transition set by law. Supply contracts signed today will run straight through the switch.

Tax reform · LC 214/2025

The transition set by law, year by year

How the tax burden on goods and services shifts from the current system to the dual VAT.

Each year: top bar, federal taxes; bottom bar, state and municipal.

  1. 2026

    Test year: CBS 0.9% and IBS 0.1%, no added burden

  2. 2027

    CBS replaces PIS and Cofins · Selective Tax begins

  3. 2028

    IBS still in test mode

  4. 2029

    ICMS and ISS at 90%

  5. 2030

    ICMS and ISS at 80%

  6. 2031

    ICMS and ISS at 70%

  7. 2032

    ICMS and ISS at 60%

  8. 2033

    Full IBS · ICMS and ISS repealed

Basis: EC 132/2023 and LC 214/2025. Statutory timetable, which may change through legislation or regulation. For information only; not a substitute for case-by-case analysis.

Section 03 · Regulatory milestones

Twenty years of regulation in seven moves

Browse the timeline: each milestone opened a stage of the chain, and 2026 rewrote the production rules.

2006
Law 11.343/2006

The legal seed: the law allows for authorized cultivation

The Drug Law bans planting, but the sole paragraph of Article 2 lets the federal government authorize cultivation for medical and scientific purposes. Twenty years later, the cultivation framework rests on that opening.

2015
RDC 3/2015 and RDC 17/2015 · ANVISA

CBD leaves the banned list: imports are regulated

In January, RDC 3/2015 removes cannabidiol from the list of banned substances and places it under special control. In May, RDC 17/2015 regulates imports by individuals, with a prescription. The access market is born, along with the first generation of companies serving it.

2017
First registered product

The first registered medicine: the pharma pathway opens

The registration of the first cannabis-based medicine in Brazil shows that the industrial route exists, with clinical trials, pharmacovigilance and controlled prescribing. The sector stops depending on imports alone.

2019
RDC 327/2019

A “cannabis products” category: pharmacies join in

ANVISA creates a dedicated category, allows manufacturing and imports by companies and brings the product to pharmacies. This framework shapes the sector’s first commercial phase and stays in force until it is replaced in 2026.

2024
STJ · IAC 16

The courts step in: hemp is not a banned plant

In November, the Superior Court of Justice (STJ) rules that hemp, with less than 0.3% THC, is not a banned plant and that companies may grow it for exclusively medical and pharmaceutical purposes. It orders the federal government and ANVISA to regulate. Industrial uses, such as fiber and construction, stay out for lack of a law.

2025
MAPA Ordinance 1.342 · LC 214

Agriculture gets organized: seeds, deadlines and tax reform

The Agriculture Ministry (MAPA) publishes the requirements for importing Cannabis sativa seeds (Ordinance 1.342/2025), while the sector hits record patient numbers and revenue. In parallel, LC 214/2025 implements the tax reform, with the transition set to begin in 2026.

2026
RDCs 1.011 to 1.015 and 1.023/2026

The framework reset: domestic cultivation, exports and a new product regime

ANVISA publishes the most complete package in the sector’s history. RDC 1.013 regulates domestic cultivation with traceability, RDC 1.014 creates a sandbox for patient associations and RDC 1.015 replaces RDC 327. Then RDC 1.023 opens exports of APIs and products made in Brazil and allows cultivation for export. A MAPA technical note acknowledges that industrial hemp still has no rules.

Tap or click the years. The ← → arrows and dragging also work.Tap the years or swipe the card.

Section 04 · Where we work

Three fronts, read together

Health rules, structure and market usually sit with different people, at different moments. Green Growth puts all three on the same table before the decision.

Front 01

Regulation & licenses

A reading of ANVISA and MAPA rules applied to your stage: which authorization applies, which deadlines are running and what inspectors will ask for.

Front 02

Structure & tax

Corporate model, risk separation and the move to CBS and IBS, reviewed before prices and contracts are set.

Front 03

Market & partnerships

Market intelligence, connections between agribusiness, extraction and industry, and preparation for the conversation with investors.

Section 05 · Readiness check

Is your operation ready for the new framework?

Five questions, two minutes. A picture of your company’s regulatory readiness for the 2026 RDCs and the tax transition, and of what to look at first.

Question 01 / 05

No data is stored. Your result is generated in your browser.

Section 06 · Frequently asked questions

The essentials of the regulated market, straight to the point

Q.01

Can a company legally do business in Brazil’s cannabis market?

+
Yes, within the medical and pharmaceutical route. ANVISA published RDCs 1.011 to 1.015/2026, which regulate everything from cultivation to the finished product, plus a sandbox for patient associations. Companies may grow hemp and make, import and sell cannabis products with the authorizations each activity requires. Under RDC 1.023/2026, they may also export APIs and products made in Brazil and grow for export. Industrial uses outside health still have no rules.
Q.02

Is growing cannabis legal in Brazil?

+
Yes, within limits. RDC 1.013/2026 allows hemp cultivation with up to 0.3% THC for medical, pharmaceutical and research purposes, and also for export, by legal entities only, with a Special Authorization, a prior health inspection and traceability. RDC 1.012/2026 covers cultivation for research. There is no legal basis for cultivation by individuals.
Q.03

What changed with ANVISA’s RDCs 1.011 to 1.015/2026?

+
The package replaced the previous framework. RDC 1.015/2026 repealed RDC 327/2019, widened the routes of administration (oral, inhaled, buccal, sublingual and dermatological) and updated quality criteria. Compounding was provided for with isolated CBD only and depends on rules still to be issued by ANVISA. RDC 1.013/2026 regulated cultivation with mandatory traceability. RDC 1.014/2026 created a sandbox for patient associations, small-scale and non-commercial. Later, RDC 1.023/2026 opened exports and cultivation for export.
Q.04

What is the tax regime for cannabis companies in Brazil?

+
During the reform transition, the current and the new systems run side by side. Today the choice is usually between Presumed Profit and Actual Profit (Simples Nacional is barred for part of the sector), with II, IPI, PIS/Cofins-Import and ICMS on imported goods. Over the transition set by LC 214/2025, CBS and IBS take over the tax burden. Medical cannabis products may seek the reduced health rate under the same law, but the classification is not automatic and depends on the case.
Q.05

Can industrial hemp already be grown for fiber, construction or food?

+
Not yet. The STJ (IAC 16, 2024) allowed hemp cultivation only for medical and pharmaceutical purposes and noted there is no legal basis for other industrial uses. A MAPA technical note acknowledged this gap and proposed guidelines to regulate the crop, with agricultural authorization, traceability and industrial end use. Until the rule comes out, these uses have no regular path in the country.
Q.06

How do I keep up with changes to the framework?

+
The rules are still moving: ANVISA, MAPA and the tax reform publish adjustments throughout the year. The monthly Green Growth newsletter sums up what changed, with the source of every number. For a reading of your case, talk to Green Growth.

For information only. Not a substitute for case-by-case legal analysis.

Monthly newsletter

Regulatory intelligence, monthly.

Regulation, tax and the cannabis and hemp market in Brazil, once a month, with the source of every number.

MonthlyNo spamFirst issue coming soon
Let's talk

Which stage of the chain is your company in?

Tell us where in the chain your project sits. The conversation starts there: what the rules require at that stage, where things usually stall and where the business is.

Coverage

B2B · nationwide

It takes about a minute. The summary goes to your WhatsApp, ready to send.

Message ready. We opened WhatsApp with the summary; just tap send. If it did not open, write to [email protected].